US Stem Cell Stock

US Stem Cell AAQS

The The AAQS of US Stem Cell (USRM) as of Aug 13, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

US Stem Cell has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock US Stem Cell in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
Access this data via the Eulerpool API

US Stem Cell Stock analysis

What does US Stem Cell do? US Stem Cell Inc is a company specializing in the field of regenerative medicine. It was founded in 1999 and is headquartered in Sunrise, Florida. The company has experienced rapid development in recent years and is one of the leading providers of stem cell therapies in the USA. The business model of US Stem Cell is based on the development and marketing of stem cell products and therapies that are intended to help patients improve their health and treat diseases. The company focuses on a range of therapeutic applications, such as the treatment of degenerative diseases, injuries, and chronic pain. US Stem Cell operates several divisions, including the Cell Processing and Storage Center, which specializes in the processing and storage of stem cells. The company also has its own research and development team that develops products and therapies and subjects them to clinical trials. US Stem Cell offers various products and therapies, including autologous stem cell therapy. In this treatment, stem cells are taken from the patient's own body, processed, and then used at the affected site. This is intended to aid in the regeneration of damaged tissue and reduce inflammation in the body. Another treatment method is the use of exogenous stem cells sourced from other donors. US Stem Cell has also entered into a partnership with the Advanced Regenerative Manufacturing Institute (ARMI) to research and develop technology for the production of biological materials and tissues. This collaboration aims to increase the availability of stem cell therapies and advance research in this field. US Stem Cell has experienced some controversies in recent years, particularly related to the use of inappropriate protocols and the performance of stem cell therapies without sufficient scientific evidence. However, the company has emphasized that their therapies are based on scientific knowledge and rigorous protocols, and that they work closely with medical professionals to ensure the safety and efficacy of their treatments. Overall, US Stem Cell Inc has established itself as a significant player in the field of regenerative medicine, particularly in the area of stem cell therapy. The company is committed to developing new therapies that help patients improve their quality of life and treat diseases. Despite some controversies, US Stem Cell remains an important and promising company in the biotechnology industry. US Stem Cell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about US Stem Cell stock

The AAQS of US Stem Cell is 2 in 2026.

On Eulerpool you can find the complete historical development of The AAQS US Stem Cell since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

Quality — US Stem Cell

All Key Metrics — US Stem Cell